Sera Prognostics (NASDAQ:SERA) Stock Price Down 2.8% – Should You Sell?

Sera Prognostics, Inc. (NASDAQ:SERA)’s share price fell 2.8% during trading on Thursday . The company traded as low as $2.78 and last traded at $2.80. 24,971 shares were traded during trading, a decline of 54% from the average session volume of 54,412 shares. The stock had previously closed at $2.88.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Jefferies Financial Group upgraded shares of Sera Prognostics to a “strong-buy” rating in a report on Monday, December 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sera Prognostics in a research note on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Sera Prognostics from a “sell” rating to a “hold” rating in a research report on Saturday, October 25th. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $5.00.

Sera Prognostics Stock Performance

The firm has a market capitalization of $108.08 million, a PE ratio of -3.64 and a beta of 0.99. The firm’s 50 day moving average price is $3.32 and its 200-day moving average price is $3.11.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.03. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.10 million. Sera Prognostics had a negative return on equity of 41.69% and a negative net margin of 34,343.16%. On average, equities research analysts expect that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

Insider Activity at Sera Prognostics

In other news, CEO Zhenya Lindgardt sold 28,215 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $3.04, for a total transaction of $85,773.60. Following the completion of the transaction, the chief executive officer directly owned 768,081 shares of the company’s stock, valued at $2,334,966.24. This represents a 3.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold 52,587 shares of company stock valued at $163,108 in the last three months. 13.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Sera Prognostics

Several institutional investors and hedge funds have recently added to or reduced their stakes in SERA. Wealth Enhancement Advisory Services LLC purchased a new position in Sera Prognostics during the fourth quarter valued at $31,000. Abel Hall LLC acquired a new position in shares of Sera Prognostics during the 2nd quarter worth about $31,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Sera Prognostics during the 3rd quarter worth about $38,000. Riverview Capital Advisers LLC purchased a new position in Sera Prognostics in the 2nd quarter valued at about $35,000. Finally, Lido Advisors LLC acquired a new stake in Sera Prognostics in the 3rd quarter worth about $68,000. Hedge funds and other institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.